RE-OPEN: Randomised trial of biosimilar TNK versus TPA during endovascular therapy for acute ischaemic stroke due to large vessel occlusions

Rohit Bhatia; MV Padma Srivastava; Saman Fatima; Risha Sarkar; Imnameren Longkumer; Shailesh Gaikwad; Leve S Joseph Devaranjan; Ajay Garg; Jeyaraj Pandian; Dheeraj Khurana; PN Sylaja; Shweta Jain; Deepti Arora; Aneesh Dhasan; Sanjith Aaron; Angel Miraclin T; Vijaya Pamidimukkala; Srijithesh Rajendran; Jayanta Roy; Biman Kanti Ray; Vivek Nambiar; Paul J Alapatt; Meenakshi Sharma

doi:10.1136/bmjno-2023-000531

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Rapid and timely treatment with intravenous thrombolysis and endovascular treatment (EVT) in patients with acute ischaemic stroke (AIS) and large vessel occlusion (LVO) significantly improves patient outcomes. Bridging therapy is the current standard of care in these patients. However, an incompletely answered question is whether one thrombolytic agent is better than another during bridging therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhatia et al. (2024) studied this question.

synapsesocial.com/papers/68e7691fb6db6435876de9b4 https://doi.org/10.1136/bmjno-2023-000531

View Full Paper

Ask AI

Bookmark

Share

RE-OPEN: Randomised trial of biosimilar TNK versus TPA during endovascular therapy for acute ischaemic stroke due to large vessel occlusions

Ask about this paper

Abstract

Discussion

Cite This Study

RE-OPEN: Randomised trial of biosimilar TNK versus TPA during endovascular therapy for acute ischaemic stroke due to large vessel occlusions

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading